



Innovating Technologies for Life

**ITL Limited**

ABN 16 088 212 088

**PO Box 139**

**Fyshwick Canberra**

**ACT 2609 Australia**

**t: +61 2 6280 8535**

**f: +61 2 6280 8538**

**[www.itl-limited.com](http://www.itl-limited.com)**

7 March 2007

## **ITL SECURES ADDITIONAL FUNDS FOR TINA PROJECT**

ITL's R&D TINA Project has been boosted by additional grant funds from the Commonwealth Government's R&D Start Programme. Based on the success of the project to date, ITL has been awarded an additional \$677,000 to extend the TINA project timeline out to 2008.

Under the TINA Project (Transfusion Infusion Needle Assembly) ITL is developing the second generation automatic retractable needle safety devices for use in blood collection, kidney dialysis, blood sampling and oncology procedures. R&D Start grant funds will assist ITL bring its first two safety needles for blood collection and kidney dialysis closer to market.

ITL's CEO Bill Mobbs said

"We are delighted with the Government's continued support. The TINA Project is progressing well and we are attracting strong interest in the marketplace.

The recent signing of the Fresenius co-operation agreement to conduct trials with the first two products emerging from the TINA product pipeline is testament to the rigor of ITL's product development process.

Fresenius is the world's largest supplier of kidney dialysis services and one of the top five blood pack manufacturers in the world. Fresenius will trial the new TINA products for kidney dialysis and blood collection procedures."

ITL already produces the global standard in safety devices for blood collection. These newly developed products will provide more sophisticated, integrated solutions for blood collection and kidney dialysis that are simpler and safer for healthcare workers to use.

ITL is constantly introducing innovative products to the market, which are underpinned by strong patent protection. Last year ITL invested 9.0% of Revenue in its product pipeline. The TINA R&D Project is funded 50% by government grants.

Bill Mobbs  
CEO ITL Limited

### *The TINA Project*

The TINA (Transfusion Infusion Needle Assembly) Project is one of ITL's leading R&D projects. Underpinned by ITL's patented technology the TINA Project aims to develop four automatic retractable safety needle devices for use in four discrete markets, namely

- Blood Collection
- Hemodialysis / Aphaeresis
- Blood Sampling, and
- Oncology

### *R&D Start Programme (now replaced by Commercial Ready Programme)*

Commercial Ready is a competitive merit-based grant program supporting innovation and its commercialisation. It aims to stimulate greater innovation and productivity growth in the private sector by providing around \$200 million per year in competitive grants to small and medium-sized businesses. A wide range of project activities are supported, extending from initial research and development (R&D), through proof of concept, to early-stage commercialisation activities.

*ITL (ASX: ITD, [www.itl-limited.com](http://www.itl-limited.com)) is a rapidly emerging multinational in the healthcare industry. ITL specialises in creating innovative medical devices and procedure packs for global healthcare markets. ITL manufactures in Australia and Malaysia, and has representative offices in North America, Europe and Asia.*

*ITL patented products have a presence in over 35 countries and protect the lives and health of healthcare workers in millions of procedures annually. ITL supplies its range of customized procedure packs to over 200 public and private hospitals across Australia as well as capital equipment, instruments and procedure packs to over 160 private and public hospitals and agents in Malaysia.*